LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

Cho, B.C.; Rodríguez-Abreu, Delvys; Hussein, Maen; Cobo, Manuel; Patel, Anjan; Sečen, Nevena; Gerstner, Gregory J.; Dw, Kim; Yg, Lee; Su, W.; Huang, Eric; Patil, Namrata; Huang, M.; Zhang, Z.; Wen, Xuejun; Mendus, Diana; Hoang, Tien; Meng, Robin; Johnson, Melissa L.

doi:10.1016/j.annonc.2021.10.217

Cited by 20 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tiragolumab is an anti-TIGIT antibody that might enhance the efficacy of PD-L1 antibody. In lung cancer, a combined treatment that included an anti-TIGIT antibody showed a positive result (Cho et al, 2021). The LEAP-014 trial is evaluating the combination of lenvatinib and chemotherapy plus an ICI.…”

mentioning

confidence: 99%

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Yamamoto

Kato

2022

Cancer Cell

View full text Add to dashboard Cite

mentioning

confidence: 99%

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Yamamoto

Kato

2022

Cancer Cell

View full text Add to dashboard Cite

“…In December 2021, the CITYSCAPE phase 2 randomized trial revealed that the addition of the anti-TIGIT antibody tiragolumab to atezolizumab significantly improved the efficacy and was associated with similar tolerability versus those observed with atezolizumab plus placebo as first-line treatment for metastatic NSCLC. The clinical benefit was more pronounced in the subgroup with PDL1 TPS ≥50% ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis

Liu

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

In this study, a bibliometric analysis was carried out to identify the most influential clinical studies and research trends on anti-programmed cell death 1/programmed cell death 1 ligand 1 (anti-PD1/PDL1) immunotherapy. On January 1, 2022, we used Web of Science to identify the 100 most frequently cited papers on clinical studies investigating anti-PD1/PDL1 immunotherapy, and extracted the following data: publication year, source title, country/region, institution, and the total number of citations. The research design and area were classified independently by the authors. Subsequently, we carried out a bibliometric analysis to determine the trends and identify the major journals on anti-PD1/PDL1 immunotherapy. The authors analyzed the current research hotspots based on papers published in major journals from 2020 to 2021. These 100 papers were cited a total of 138,840 times, and the median number of citations was 899.5 (range: 341–7,983). “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer” by Topalian et al. had the highest number of citations (7,983 times). New England Journal of Medicine had the highest number of top-cited papers (40 papers), average citations per paper (1,558.3 citations), and rate of top-cited papers (65.6%). Authors from the USA contributed most of the papers (76 papers). Lung cancer (30 papers, 46,422 citations) and melanoma (20 papers, 30,881 citations) were the most cited research areas. In summary, anti-PD1/PDL1 has become standard treatment for various cancer, while adjuvant anti-PD1/PDL1 therapy is currently a research hotspot. New England Journal of Medicine was identified as the most influential journal in this area. Non-small cell lung cancer and melanoma are the most well-studied cancers, while nivolumab and pembrolizumab are the most commonly investigated anti-PD1/PDL1 antibodies. Further studies are warranted to identify effective predictive biomarkers or models, clarify the molecular mechanism of combined therapy, and establish optimal therapeutic strategies. This study may assist researchers in obtaining a comprehensive impression of the landscape and current trends in anti-PD1/PDL1 immunotherapy and gain inspiration to conduct further studies.

show abstract

“…In the subset analysis, significantly prolonged PFS was observed in the group with PD-L1 expression ≥ 50%, reaching 16.6 months (95% CI: 5.5–22.3), and the ORR reached 69.0% (95% CI: 50.4–87.5). Safety profiles were similar ( Table 2 ) [ 28 ]. The CITYSCAPE trial is the first randomised trial of an anti-TIGIT therapy and provides evidence that targeting both TIGIT and PD-L1 molecules (tiragolumab plus atezolizumab) may improve anti-tumour activity by amplifying the immune response in advanced NSCLC patients [ 28 ].…”

Section: Pathway Inhibitors Other Than Pd-1/pd-l1: Discovering New Im...mentioning

confidence: 99%

“…Safety profiles were similar ( Table 2 ) [ 28 ]. The CITYSCAPE trial is the first randomised trial of an anti-TIGIT therapy and provides evidence that targeting both TIGIT and PD-L1 molecules (tiragolumab plus atezolizumab) may improve anti-tumour activity by amplifying the immune response in advanced NSCLC patients [ 28 ].…”

Section: Pathway Inhibitors Other Than Pd-1/pd-l1: Discovering New Im...mentioning

confidence: 99%

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Krzyżanowska

Wojas‐Krawczyk

Milanowski

et al. 2022

IJMS

View full text Add to dashboard Cite

Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area.

show abstract

LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

Cited by 20 publications

References 0 publications

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Contact Info

Product

Resources

About